FOSUN PHARMA
復星医药

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The following sets out the "Announcement in Relation to the Approval of Drug Clinical Trial of a Subsidiary" published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "**Company**") on the website of the Shanghai Stock Exchange, for your reference only. The following is a translation of the above mentioned announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Chen Yuqing
Chairman

Shanghai, the PRC
8 September 2026

As at the date of this announcement, the executive directors of the Company are Mr. Chen Yuqing, Ms. Guan Xiaohui, Mr. Wen Deyong, Mr. Wang Kexin and Mr. Liu Yi; the non-executive directors of the Company are Mr. Chen Qiyu and Mr. Pan Donghui; the independent non-executive directors of the Company are Mr. Yu Tze Shan Hailson, Mr. Wang Quandi, Mr. Chen Penghui and Mr. Yang Yucheng; and the employee director of the Company is Ms. Yan Jia.

* *for identification purposes only*

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Announcement in Relation to the Approval of Drug Clinical Trial of a Subsidiary

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein contained.

I. Overview

Recently, Shanghai Fosun Pharmaceutical Industrial Development Company Limited* (上海復星醫藥產業發展有限公司) (the "**Fosun Pharma Industrial**"), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (上海復星醫藥（集團）股份有限公司) (the "**Company**") received the approval from the National Medical Products Administration for a Phase II/III adaptive seamless design clinical trial of FXS5626 (formerly project no.: AC-201, the "**FXS5626**") for the treatment of non-segmental vitiligo. Fosun Pharma Industrial intends to commence the relevant clinical trial of the drug in Chinese mainland[1] when the conditions are fulfilled.

II. Basic Information and Development Progress on FXS5626

FXS5626 is an oral small-molecule JAK inhibitor (TYK2/JAK1 dual-target inhibitor) licensed in by the Group (i.e., the Company and its subsidiaries/units, the same applies below). The Group is granted an exclusive license to research, develop, manufacture, register and commercialize the Drug in Chinese mainland, Hong Kong and Macau. FXS5626 is primarily indicated for autoimmune diseases. As of the date of this announcement (i.e. 8 September 2026, the same applies below), the Phase II clinical trial of the drug for moderate-to-severe plaque psoriasis has been completed in Chinese mainland, and the drug for non-infectious uveitis is at the stage of Phase II clinical trial in

[1] excluding Hong Kong, Macau and Taiwan for the purpose of this announcement, the same applies below.

Chinese mainland.

As of August 2026, the Group has invested approximately RMB108 million (including license fees; unaudited) in total in the research and development ("**R&D**") of FXS5626 at this stage.

According to the latest data of IQVIA CHPA[2], the sales of JAK inhibitors in Chinese mainland in 2025 was approximately RMB1,980 million. As of the date of this announcement, no TYK2/JAK1 dual-target inhibitor has been approved for launch in Chinese mainland.

III. Impact on the Listed Company and Risk Warning

As required by the relevant laws and regulations, FXS5626 is subject to undergo a series of clinical studies and approval by the relevant drug authority in Chinese mainland before it can be launched. There are certain risks in the R&D of drugs based on our experience. For example, clinical trials may be terminated due to issues such as safety and/or efficacy.

The R&D and launch of drugs is a long-term task involving various uncertainties. Investors should take note of the investment risks.

Announcement is hereby made.

Board of Directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

8 September 2026

*For identification purpose only

[2] Provided by IQVIA, a provider of professional medical and health information and strategic consultation service in the world; IQVIA CHPA data cover the drug sales market of hospitals with more than 100 beds in China, the actual sales of different drugs may vary from the IQVIA CHPA data to varying degrees due to their different sales channels.